EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Eugenol: A promising therapeutic terpenoid against ischemia-reperfusion injury

Puneet Kaur Randhawa, Deepti Gupta, Mohd Hanifa, Bivek Bajgai, Sorabh Sehajpal, Sarbeshwar Jaggi, Anjana Bali

EXCLI Journal · 19.01.2026 · 25 · 222-237

DOI: 10.17179/excli2025-9036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 19.01.2026. Verfasst von Puneet Kaur Randhawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Amritsar Group of Colleges, Amritsar, Punjab, 143001, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemic disorders are one of the prime causes of mortality and disability among various individuals across the globe. Although drug treatment/percutaneous coronary interventions may recanalize the obstructed blood vessels, yet reperfusion therapy may aggravate tissue damage and result in ischemia-reperfusion injury. Eugenol, a phenolic monoterpenoid (4-allyl-2-methoxyphenol), has been used extensively in various preclinical studies as an antioxidant compound that ameliorates ischemia-reperfusion injury in several organs, including the heart, brain, kidney, and intestine. This protective effect of eugenol is attributed to its ability to influence various several key signaling pathways. These include the AMPK-mTOR-P70S6K (AMP-activated protein kinase-mammalian target of rapamycin-p70 ribosomal S6 kinase) pathway, AMPK/GSK3β (Glycogen synthase kinase-3 beta) axis, PI3K/Akt (phoshatidylinositol-3 kinase/ protein kinase B) signaling, which help to mitigate oxidative damage and inflammation. It also modulates the activity of the Nrf2 transcription factor, ACE, and the apoptotic pathway, affects histone acetylation, and alters the expression of HMGN1, PPP2Ca, and CD151 genes, demonstrating its wide-ranging therapeutic effects. In this review, we will discuss the preclinical evidences and potential mechanisms of action of eugenol-dependent protective benefits against ischemia-reperfusion injury.

Schlagwörter

Stichwörter der Autor:innen

ACEAMPKEugenolIschemia-reperfusion injuryNrf2PI3K

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Amritsar Group of Colleges, Amritsar, Punjab, 143001, India.
  • Division of Metabolic and Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, 32827, USA.
  • Kelly Education, Orlando, USA.
  • Laboratory of Neuroendocrinology, Department of Pharmacology, Central University of Punjab, Ghudda, Bathinda, India.
  • Simon Fraser University, Burnaby, BC, Canada.

Zitieren

APA

Randhawa, P. K., Gupta, D., Hanifa, M., Bajgai, B., Sehajpal, S., Jaggi, S., & Bali, A. (2026). Eugenol: A promising therapeutic terpenoid against ischemia-reperfusion injury. EXCLI Journal, 25, 222-237. https://doi.org/10.17179/excli2025-9036

Vancouver

Randhawa PK, Gupta D, Hanifa M, Bajgai B, Sehajpal S, Jaggi S, et al. Eugenol: A promising therapeutic terpenoid against ischemia-reperfusion injury. EXCLI Journal. 2026;25:222-237. doi:10.17179/excli2025-9036

BibTeX
@article{Randhawa2026,
  author = {Randhawa, Puneet Kaur and Gupta, Deepti and Hanifa, Mohd and Bajgai, Bivek and Sehajpal, Sorabh and Jaggi, Sarbeshwar and Bali, Anjana},
  title = {Eugenol: A promising therapeutic terpenoid against ischemia-reperfusion injury},
  journal = {EXCLI Journal},
  year = {2026},
  volume = {25},
  pages = {222--237},
  doi = {10.17179/excli2025-9036}
}
Kostenlos starten →